Abstract
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
New Emirates Medical Journal
Title:Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis
Volume: 1
Author(s): Mohamed Abuzakouk*, Omar Ghorab, Safieeldin Ghazala and Anastasios Hantzakos
Affiliation:
- Department of Allergy and Immunology, Cleveland Clinic Abu Dhabi, Abu Dhabi,United Arab Emirates
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
Abstract:
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Export Options
About this article
Cite this article as:
Abuzakouk Mohamed *, Ghorab Omar , Ghazala Safieeldin and Hantzakos Anastasios , Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis, New Emirates Medical Journal 2020; 1 (2) . https://dx.doi.org/10.2174/0250688202002022006
DOI https://dx.doi.org/10.2174/0250688202002022006 |
Print ISSN 0250-6882 |
Publisher Name Bentham Science Publisher |
Online ISSN 0250-6882 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Immunological Impediments to Developing a Blood Stage Malaria Vaccine
Current Immunology Reviews (Discontinued) Role of Fc Receptors as a Therapeutic Target
Inflammation & Allergy - Drug Targets (Discontinued) Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Cartilage Regeneration by Gene Therapy
Current Gene Therapy Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches
Current Medicinal Chemistry A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Exercise Addiction- Diagnosis, Bio-Psychological Mechanisms and Treatment Issues
Current Pharmaceutical Design T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry The C-Terminal Domain of Pancreatic Lipase: Functional and Structural Analogies with C2 Domains
Current Protein & Peptide Science The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Diabetic Pregnancies: The Challenge of Developing in a Pro-Inflammatory Environment
Current Medicinal Chemistry Prevention and Treatment of Allergic Asthma in Pregnancy: From Conventional Drugs to New Therapeutical Approaches
Current Pharmaceutical Biotechnology Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections
Inflammation & Allergy - Drug Targets (Discontinued) Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets The Role of Anticoagulation in Cancer Patients: Facts and Figures
Anti-Cancer Agents in Medicinal Chemistry